XellSmart Biomedical (士泽生物医药) is a clinical-stage biotechnology company based in Suzhou and Shanghai, China, founded in 2021 by Dr. Xiang Li. The company develops clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system diseases, with NMPA- and U.S. - View it on GitHub